A Safety and Efficacy Study of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment
Status:
Completed
Trial end date:
2021-04-18
Target enrollment:
Participant gender:
Summary
This is a multicenter, open-label extension (OLE) study of ADS-5102 (amantadine extended
release [ER] capsules) in subjects with MS and walking impairment who completed a prior study
of ADS-5102 in subjects with MS.